Get the Stockscreener App
1.87
4.10%
-0.08
After Hours:
1.89
0.02
+1.07%
Aclaris Therapeutics Inc stock is traded at $1.87, with a volume of 580.89K.
It is down -4.10% in the last 24 hours and down -8.33% over the past month.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
See More
Previous Close:
$1.95
Open:
$1.97
24h Volume:
580.89K
Relative Volume:
0.56
Market Cap:
$202.58M
Revenue:
$27.08M
Net Income/Loss:
$-37.00M
P/E Ratio:
-3.5962
EPS:
-0.52
Net Cash Flow:
$-18.46M
1W Performance:
+0.54%
1M Performance:
-8.33%
6M Performance:
+73.15%
1Y Performance:
+61.21%
1-Day Range:
$1.855
$1.97
1-Week Range:
$1.84
$1.97
52-Week Range:
$1.05
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Name
Aclaris Therapeutics Inc
Sector
Industry
Phone
484-324-7933
Address
701 LEE ROAD, WAYNE, PA
Compare ACRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
1.87 | 211.25M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Piper Sandler | Overweight |
| May-28-25 | Initiated | Wedbush | Outperform |
| Mar-18-25 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-23-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-19-24 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-19-24 | Upgrade | Jefferies | Hold → Buy |
| Nov-19-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-18-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-22-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-03-23 | Initiated | Evercore ISI | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Oct-06-22 | Initiated | BTIG Research | Buy |
| Jul-23-21 | Resumed | Jefferies | Buy |
| Jun-15-21 | Initiated | Piper Sandler | Overweight |
| Apr-21-21 | Initiated | H.C. Wainwright | Buy |
| Oct-22-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-06-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jun-27-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-06-19 | Initiated | SVB Leerink | Outperform |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Feb-09-18 | Initiated | Guggenheim | Buy |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-29-16 | Initiated | Leerink Partners | Outperform |
| Sep-30-16 | Initiated | JMP Securities | Mkt Outperform |
| Jun-10-16 | Initiated | Guggenheim | Buy |
| Nov-02-15 | Initiated | Citigroup | Buy |
| Nov-02-15 | Initiated | Jefferies | Buy |
View All
Aclaris Therapeutics Inc Stock (ACRS) Latest News
Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Invest In Growth? - Yahoo Finance
Building trade automation scripts for Aclaris Therapeutics Inc.2025 Trade Ideas & Weekly Momentum Picks - newser.com
Full technical analysis of Aclaris Therapeutics Inc. stock2025 Investor Takeaways & Real-Time Sentiment Analysis - newser.com
Real time alert setup for Aclaris Therapeutics Inc. performanceQuarterly Portfolio Review & Fast Exit and Entry Trade Guides - newser.com
Real time breakdown of Aclaris Therapeutics Inc. stock performanceJuly 2025 Technicals & Fast Exit and Entry Trade Guides - newser.com
Is Aclaris Therapeutics Inc. (8AT) stock testing key supportGDP Growth & Stock Portfolio Risk Control - newser.com
Atopic Dermatitis Pipeline Outlook Report 2025: Insight into emerging drugs, treatment options, clinical trials, and company strategies - The Globe and Mail
What analysts say about Aclaris Therapeutics Inc 8AT stockMarket Sentiment Shifts & Outperform the Market with Aggressive Picks - earlytimes.in
How Aclaris Therapeutics Inc. stock performs during Fed tightening cyclesEarnings Recap Report & Weekly Top Gainers Alerts - newser.com
Sentiment analysis tools applied to Aclaris Therapeutics Inc.July 2025 Catalysts & Risk Adjusted Buy/Sell Alerts - newser.com
Will Aclaris Therapeutics Inc. rebound enough to break evenRate Cut & High Accuracy Trade Signal Alerts - newser.com
Risk vs reward if holding onto Aclaris Therapeutics Inc.July 2025 Earnings & Reliable Volume Spike Alerts - newser.com
Real time scanner hits for Aclaris Therapeutics Inc. explainedCEO Change & Daily Stock Trend Reports - newser.com
Will Aclaris Therapeutics Inc. (8AT) stock profit from automation waveGold Moves & High Yield Equity Trading Tips - newser.com
Using fundamentals and technicals on Aclaris Therapeutics Inc.Weekly Market Report & High Yield Stock Recommendations - newser.com
Aclaris to Host 2025 R&D Day in New York to Spotlight Immuno-Inflammatory Pipeline - MyChesCo
Using Bollinger Bands to evaluate Aclaris Therapeutics Inc.July 2025 PostEarnings & High Yield Stock Recommendations - newser.com
How high can Aclaris Therapeutics Inc. stock goCPI Data & Free Community Supported Trade Ideas - newser.com
Will Aclaris Therapeutics Inc. (8AT) stock beat revenue estimatesWeekly Trade Review & Accurate Intraday Trade Tips - newser.com
Published on: 2025-10-02 23:56:18 - newser.com
What drives Aclaris Therapeutics Inc stock priceBreakout Stock Watch & Exceptional Return Investment - earlytimes.in
Does Aclaris Therapeutics Inc. qualify in momentum factor screeningWeekly Risk Summary & Precise Buy Zone Tips - newser.com
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, “Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025 - Sahm
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, "Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets", in New York on October 14, 2025 - Investing News Network
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, 'Patient Focused Innovation: Addressing Gaps in Immuno-Inflammatory Markets”, in New York on October 14, 2025 - The Manila Times
Aclaris Therapeutics to Host In-Person and Webcast R&D Day, - GlobeNewswire
Major Immuno-Inflammatory Pipeline Updates: Aclaris R&D Day to Showcase Novel Kinase Inhibitor Progress - Stock Titan
How to read the order book for Aclaris Therapeutics Inc.2025 Sector Review & Community Consensus Trade Alerts - newser.com
Aclaris Therapeutics Inc Stock (ACRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aclaris Therapeutics Inc Stock (ACRS) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mehra Anand | Director |
Nov 19 '24 |
Buy |
2.25 |
666,666 |
1,499,998 |
710,030 |
5.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):